ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Glenn Baity sold 26,507 shares of the company’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $34.87, for a total transaction of $924,299.09. Following the transaction, the executive vice president now owns 94,163 shares in the company, valued at approximately $3,283,463.81. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Glenn Baity also recently made the following trade(s):

  • On Wednesday, August 9th, Glenn Baity sold 14,322 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $34.88, for a total transaction of $499,551.36.
  • On Thursday, July 20th, Glenn Baity sold 38,097 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $30.00, for a total transaction of $1,142,910.00.
  • On Thursday, June 22nd, Glenn Baity sold 1,903 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $30.00, for a total transaction of $57,090.00.

ACADIA Pharmaceuticals Inc. (ACAD) traded up 1.54% on Friday, hitting $36.16. The stock had a trading volume of 1,400,040 shares. The company has a 50-day moving average of $30.91 and a 200 day moving average of $31.79. The company’s market cap is $4.43 billion. ACADIA Pharmaceuticals Inc. has a 12 month low of $20.68 and a 12 month high of $40.83.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.17. The business had revenue of $30.50 million during the quarter, compared to analysts’ expectations of $20.02 million. ACADIA Pharmaceuticals had a negative return on equity of 62.00% and a negative net margin of 221.30%. The business’s revenue was up 30400.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.63) earnings per share. On average, analysts predict that ACADIA Pharmaceuticals Inc. will post ($2.55) EPS for the current fiscal year.

WARNING: This article was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/01/insider-selling-acadia-pharmaceuticals-inc-acad-evp-sells-26507-shares-of-stock.html.

Hedge funds have recently modified their holdings of the company. FMR LLC boosted its stake in shares of ACADIA Pharmaceuticals by 0.5% in the second quarter. FMR LLC now owns 18,306,966 shares of the biopharmaceutical company’s stock valued at $510,582,000 after buying an additional 95,823 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of ACADIA Pharmaceuticals by 1.8% in the second quarter. Vanguard Group Inc. now owns 7,604,605 shares of the biopharmaceutical company’s stock valued at $212,093,000 after buying an additional 134,820 shares during the last quarter. BlackRock Inc. boosted its stake in shares of ACADIA Pharmaceuticals by 2.9% in the second quarter. BlackRock Inc. now owns 5,590,706 shares of the biopharmaceutical company’s stock valued at $155,925,000 after buying an additional 157,497 shares during the last quarter. OppenheimerFunds Inc. boosted its stake in shares of ACADIA Pharmaceuticals by 3.6% in the first quarter. OppenheimerFunds Inc. now owns 4,918,286 shares of the biopharmaceutical company’s stock valued at $169,090,000 after buying an additional 170,289 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of ACADIA Pharmaceuticals by 15.8% in the second quarter. State Street Corp now owns 3,748,468 shares of the biopharmaceutical company’s stock valued at $104,551,000 after buying an additional 510,670 shares during the last quarter. Hedge funds and other institutional investors own 97.11% of the company’s stock.

Several equities analysts have issued reports on ACAD shares. HC Wainwright restated a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday, May 10th. Zacks Investment Research upgraded shares of ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, May 12th. Rodman & Renshaw restated a “buy” rating and set a $60.00 target price on shares of ACADIA Pharmaceuticals in a research note on Monday, May 22nd. ValuEngine upgraded shares of ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Finally, BidaskClub upgraded shares of ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $43.23.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.